This article was originally published in Start Up
Executive SummaryLooking for high acquisition valuations like those paid for Lifescan by J&J and for Medisense by Abbott, a host of new diabetes start-ups are trying to develop alternatives to finger-stick home glucose testing. Most companies are developing less-invasive or non-invasive technologies to reduce or entirely eliminate the pain of testing. LXN, on the other hand, is aiming to improve glucose control through an at-home version of the state-of-the-art glycated protein test.
You may also be interested in...
Dr Reddy’s sees its Indian domestic market and China as hot prospects as it pursues its “transformation journey” in which it is reducing its dependence on the slowing US market.
Glenmark has struck a deal with private equity firm True North for its gynecology business in India and Nepal.